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Abstract
Emergence and spread of extended spectrum beta-lactamase (ESBL)-producing gram-negative bacteria, mainly due to
CTX-M, is a major global public health problem. Patients infected with ESBL-producing gram-negative bacteria have an
increased risk of treatment failure and death. We investigated the prevalence and risk factors for CTX-M gram-negative
bacteria isolated from clinical specimens of patients hospitalized at a tertiary care hospital in Kilimanjaro, Tanzania.
Isolated gram-negative bacteria from inpatients admitted at Kilimanjaro Christian Medical Centre (KCMC) between
August 2013 and August 2015 were fully genome sequenced. The prevalence of ESBL-producing gram-negative bac-
teria was determined based on the presence of blaCTX-M. The odds ratio (OR) and risk factors for ESBL-producing gram-
negative bacteria due to CTX-M were assessed using logistic regression models. The overall CTX-M prevalence (95%
CI) was 13.6% (10.1–18.1). Adjusted for other factors, the OR of CTX-M gram-negative bacteria for patients previously
hospitalized was 0.26 (0.08–0.88), p = 0.031; the OR for patients currently on antibiotics was 4.02 (1.29–12.58), p =
0.017; the OR for patients currently on ceftriaxone was 0.14 (0.04–0.46), p = 0.001; and the OR for patients with wound
infections was 0.24 (0.09–0.61), p = 0.003. The prevalence of ESBL-producing gram-negative bacteria due to CTX-M in
this setting is relatively low compared to other previous reports in similar settings. However, to properly stop further
spread in the hospital, we recommend setting up a hospital surveillance system that takes full advantage of the available
next-generation sequencing facility to routinely screen for all types of bacterial resistance genes.
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Introduction
Existence of antibiotic resistance due to extended spectrum
beta-lactamase (ESBL)-producing gram-negative bacteria is
a major global public health problem [1] and has been report-
ed in all regions of the world [2–7]. Compared to patients
infected with beta-lactam susceptible bacteria, patients infect-
ed with ESBL-producing gram-negative bacteria put a greater
burden on health-care resources and have an increased risk of
treatment failure and poor outcomes including death [8, 9].
High-income countries (HICs) have surveillance systems in
place to estimate the burden of bacterial infections due to
ESBL-producing gram-negative bacteria, and to determine
risk factors for acquisition of ESBL-producing gram-negative
bacteria as well as the clinical outcomes associated with infec-
tion [1, 10–12]. In Sub-Sahara Africa (SSA), data on ESBL-
producing gram-negative bacteria epidemiology and risk fac-
tors associated with ESBL-producing gram-negative bacteria
infection are scarce. When available, the data mostly origi-
nates from hospital-based studies [13–18]. Several risk factors
have been documented to be associated with ESBL-producing
gram-negative bacteria acquisition, including previous hospi-
talization, previous use of antibiotics such as third-generation
cephalosporins, hospital overcrowding, bed sharing when
hospitalized, and international travel [19–25].
In 2002, Blomberg et al. reported high proportions of in-
fections due to ESBL-producing gram-negative bacteria at the
National Hospital in Dar es Salaam, Tanzania [26]. Since then,
other reports have shown an increasing trend of ESBL-
producing gram-negative bacteria infections in the same hos-
pital [14, 27–29]. Similarly, studies conducted at a tertiary
hospital in Mwanza, Tanzania have documented an increase
in ESBL-producing gram-negative bacteria infections [28, 30,
31]. Like the centers in Dar es Salaam and Mwanza,
Kilimanjaro Christian Medical Centre (KCMC) is a major
zonal tertiary healthcare facility, serving nearly one quarter
of Tanzania’s estimated 53.5 million inhabitants [32]. Its set-
ting however sets KCMC apart: the Kilimanjaro region in
Tanzania has among the highest international movements of
people in the country for tourism and business. The region has
four distinct ecosystems inhabited by diverse communities of
miners, pastoralists, agrarians, and fishermen. Given the pub-
lic health importance of ESBL-producing gram-negative bac-
teria, the role that KCMC plays in guiding empirical treat-
ment, and the need for therapeutic decisions to be based on
guidelines which are derived from local epidemiological data
[33], a study on ESBL-producing gram-negative bacteria in
KCMC was found to be imperative. In our setting, little atten-
tion is paid to gram-negative bacteria, although they have
been reported in east Africa and elsewhere to be causes of
outbreaks and to be main contributors of ESBL resistance
due to production of CTX-M [13, 34]. The aim of this study
was to determine the proportion estimates and risk factors for
ESBL-producing gram-negative bacteria due to CTX-Musing
whole genome sequences of all gram-negative bacteria iso-
lated from clinical specimens at KCMC hospital.
Materials and methods
Study design, participants, and specimen collection
A hospital-based cross-sectional study was conducted at KCMC
between August 2013 and August 2015. Geographically,
KCMC is located in north-eastern Tanzania and serves as a zonal
referral hospital. The hospital has a bed capacity of 650 with
approximately 500 outpatients seeking medical services daily.
The study involved patients admitted in medical, surgical,
and pediatrics wards who were suspected to have bacterial
infection. A written consent was obtained from each partici-
pant or from parents or guardians of children before enrolment
into the study. Clinical specimens collected for bacterial cul-
ture were sputum, wound or pus swab, stool, and blood.
Bacterial culture and identification
Bacteria culture, isolation, and identification were performed
according to in-house standard operating procedures as well
as the Clinical and Laboratory Standards Institute (CLSI)
guidelines as described by Kumburu et al. [35].
Genomic DNA isolation, whole genome sequencing,
and analysis
Bacterial genomic DNA (gDNA) was purified and its concen-
tration determined using the Easy-DNA extraction kit
Invitrogen® and the Qubit dsDNA Assay Kit Invitrogen®
respectively. The gDNA library preparation was performed
following Nextera® XT DNA Sample Preparation Guide
[36]. In brief, each gDNA was tagmented (tagged and
fragmented) by the Nextera® XT transposome. The
transposome simultaneously fragments the input DNA and
adds adapter sequences to the ends. Thereafter followed a
limited-cycle PCR amplification whereby indexes required
for cluster formation were added to each DNA piece. Then
each gDNA library was normalized to ensure equal represen-
tation during sequencing. Equal volumes of the normalized
library were combined, diluted in hybridization buffer, and
heat-denatured prior to sequencing on the Illumina MiSeq
platform (Illumina, Inc., San Diego, CA). Whole genome se-
quence reads were analyzed using bioinformatics tools avail-
able on https://cge.cbs.dtu.dk/services/. For this report’s
purpose, the analyses included de novo reads assembly,
species identification, and determination of blaCTX-M
encoding ESBL.
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Collection of metadata and statistical analyses
Case report and laboratory result forms designed for this study
were used to collect metadata. Double data entry was per-
formed in OpenClinica (OpenClinica LLC, MA USA). Stata
version 13 (StataCorp LP, Texas 77845 USA) was used for all
statistical analyses. The prevalence of resistance due to ESBL-
producing gram-negative bacteria was calculated as the num-
ber of gram-negative bacteria positive for blaCTX-M divided by
total number of gram-negative bacteria sequenced. The prev-
alence across levels of a categorical variable, such as age,
gender, wards admitted, type of bed, hospitalization, antibi-
otics use, disease conditions, and comorbidities, was com-
pared using Chi-square test or Fisher’s exact test. Logistic
regression was performed to determine risks of isolating
CTX-M gram-negative bacteria strains from patients. In the
multivariate analysis, we included any variable whose p value
≤ 10% and those that were considered key risk factors regard-
less of their p values being > 10% in univariate analysis.
Statistical significance of associations was decided based on
a two-tailed p value and respective 95% confidence intervals.
Results
Study population
In total, 575 patients were included in this study (Table 1).
These baseline data have also been presented before by
Kumburu et al. [35]. The median age in years (IQR) was 43
(30–57), and 348 (60.6%) of the patients were males. Three
hundred thirty nine (59.2%) had primary education level and
271 (47.3%) were farmers. A total of 301 (52.3%) patients
were admitted into medical wards. One hundred six (18.4%)
of all patients were on stretcher type beds. A total of 287
(49.9%) specimens were wound and/or pus swabs.
A total of 263 (45.9%) patients had infected wounds, 81
(14.1%) had pneumonia, and 20 (3.5%) had diarrhea. A total
of 60 (10.5%) were TB, 81(14.1%) were HIV, and 122
(21.3%) were diabetic cases. Out of all participants, 412
(71.9%) were on antibiotics at the time specimens were col-
lected (Table 1).
Prevalence of CTX-M in gram-negative bacteria
A total of 590 specimens were collected in the following
distribution: 56 were stool, 122 were sputum, 126 were blood,
and 286 were wound or pus swabs. Of all the specimens, 249
were culture-positive yielding 377 bacterial isolates that were
fully sequenced. Of these, 287 bacterial isolates were gram-
negative bacteria. The most prevalent gram-negative bacteria
were Proteus spp. (n = 48, 16.7%), Escherichia coli (n = 44,
15.3%), Pseudomonas spp. (n = 40, 13.9%), and Klebsiella
spp. (n = 38, 13.2%). The CTX-M gene was found in 39 of
the 287 gram-negative bacteria, yielding an overall prevalence
(95% CI) of 13.6% (10.1–18.1) (Table 2). The prevalence in
isolates from those admitted in surgical, medical, and ICU
wards, respectively, were 5.0% (2.5–9.8), 9.4% (4.7–17.8),
and 3.1% (0.4–19.8). Table 2 shows also crude odds ratios
(OR) for different patient characteristics. The crude OR
(95%CI) of CTX-M gram-negative bacteria in patients admit-
ted in medical wards was significantly higher compared to
those from surgical wards; OR 3.62 (1.74–7.52), p = 0.001.
Bacterial isolates from those sleeping in ward corridors/
Table 1 Demographic and clinical characteristics of the study
population
Patient characteristic Total
Number of patients 575 (100)
Median age in years (IQR) 43 (30–57)
Gender
Female 226 (39.4)
Male 348 (60.6)
Occupation
Farming 271 (47.3)
Employed 177 (30.9)
Other 125 (21.8)
Education level
No 130 (22.7)
Primary 339 (59.2)
Secondary/Above 104 (18.2)
Ward of admission
Surgical 257 (44.7)
Medical 301 (52.3)
Other 17 (3.0)
Location of patient
In Corridor/Stretcher 106 (18.4)
Inside room/Bed 469 (81.6)
Specimen collected
Blood 117 (20.3)
Sputum 120 (20.9)
Stool 51 (8.9)
Swabs (wound or pus) 287 (49.9)
Comorbid conditions
Wound 263 (45.9)
Pneumonia 81 (14.1)
Tuberculosis 60 (10.5)
Sepsis, septicemia 113 (19.7)
Diarrhea 20 (3.5)
Diabetes 122 (21.3)
HIV 81 (14.1)
Cancer 52 (9.1)
Currently on antibiotics 412 (71.9)
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stretchers had a prevalence of 7.4% (3.9–13.7), versus 4.8%
(2.4–9.4) for those sleeping inside rooms/beds (Table 2).
Prevalence of ESBL-producing gram-negative bacteria due
to CTX-M per different disease conditions was investigated
(Table 3). Among patients with wound infections, the preva-
lence was 4.2% (2.0–8.6) while among diarrhea cases, TB
cases, and patients with sepsis, the prevalence was 2.0%
(4.6–56.3), 6.7% (0.9–37.1), and 2.9% (0.7–11.3), respective-
ly. Furthermore, ESBL-producing gram-negative bacteria
prevalence due to CTX-M in HIV and in diabetic cases was
11.1% (3.5–30.0) and 8.5% (3.8–17.7), respectively.
Table 3 further documents crude ORs for different morbid-
ities. Crude OR of CTX-M gram-negative bacteria in patients
with wounds was significantly lower compared to those who
did not have wounds; OR 0.28 (0.14–0.58), p = 0.001, while
the crude OR of CTX-M gram-negative bacteria in patients
with diarrhea was significantly higher compared to those with-
out; OR 11.0 (2.94–40.98), p = 0.001. The trend for OR of
infection with CTX-M gram-negative bacteria among HIV
cases was higher compared to non-HIV cases; OR 2.46
(0.96–6.30), p = 0.06.
We also investigated the prevalence of CTX-M gram-neg-
ative bacteria in patients on different antibiotics (Table 4). The
prevalence of CTX-M gram-negative bacteria in patients on at
least one antibiotic was 6.8% (4.1–10.9). The OR of CTX-M
gram-negative bacteria when patients were on other
Ceftriaxone as compared to those who were not showed that
those on Ceftriaxone had a reduced risk; OR 0.34 (0.16–0.71),
p = 0.004, while there was a trend that those on Ciprofloxacin
had an increased risk of CTX-M gram-negative bacteria; OR
2.62 (0.88–7.83), p = 0.084.
Risk factors for CTX-M gram-negative bacteria
Table 5 shows adjusted OR (AOR) for various patient charac-
teristics. After adjusting for other patient characteristics,
Table 2 Socio-demographic
characteristics of patients from
which CTX-M gram-negative
bacteria were isolated
Patient characteristics CTX-M gram-negative bacteria
Prevalence (95% CI) Crude OR (95% CI) P value
All CTX-M 13.6 (10.1–18.1) – –
Age (years)
0–35(n = 87) 4.6 (1.7–11.7) 1 (Ref) –
36–53(n = 84) 6.0 (2.5–13.6) 1.27 (0.53–3.01) 0.595
54 and above (n = 100) 8.0 (4.0–15.3) 1.12 (0.48–2.63) 0.786
Departmenta
SW (n = 159) 5.0 (2.5–9.8) 1 (Ref) –
MW (n = 85) 9.4 (4.7–17.8) 3.62 (1.74–7.52) 0.001
ICU (n = 32) 3.1 (0.4–19.8) 0.69 (0.15–3.20) 0.636
Hospital stay (days)
0–4 (n = 82) 7.3 (3.3–15.5) 1 (Ref) –
5–12 (n = 91) 6.6 (3.0–14.0) 1.05 (0.47–2.36) 0.911
13 and above (n = 86) 3.5 (1.1–10.4) 0.47 (0.18–1.25) 0.129
Gender
Female (n = 111) 4.5 (1.9–10.4) 1 (Ref) –
Male (n = 166) 7.2 (4.1–12.3) 0.91 (0.45–1.82) 0.783
History of hospitalization
No (n = 188) 6.4 (3.6–10.9) 1 (Ref) –
Yes (n = 99) 5.1 (2.1–11.7) 0.53 (0.24–1.16) 0.111
History of medication
No (n = 109) 3.7 (1.4–9.4) 1 (Ref) –
Yes (n = 178) 7.3 (4.3–12.2) 1.26 (0.62–2.58) 0.521
Current medication
No (n = 81) 8.6 (4.1–17.2) 1 (Ref) –
Yes (n = 206) 4.9 (2.6–8.8) 1.0 (0.47–2.12) 0.998
Patient location
Inside room/Beds (n = 166) 4.8 (2.4–9.4) 1 (Ref) –
Corridor/Stretcher (n = 121) 7.4 (3.9–13.7) 0.94 (0.48–1.88) 0.877
a sw surgical ward, mw medical ward, ICU intensive care unit
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several variables appeared to be statistically associated with
CTX-M gram-negative bacteria. These variables include prior
admission, currently on antibiotics, currently on ceftriaxone,
and wound infections. Those with a prior admission history
Table 3 Morbidity types and
prevalence of CTX-M gram-
negative bacteria
Patient characteristics CTX-M gram-negative bacteria
Prevalence (95% CI) Crude OR (95% CI) P value
Infected wounds
No (n = 109) 9.2 (4.9–16.3) 1 (Ref) –
Yes (n = 167) 4.2 (2.0–8.6) 0.28 (0.14–0.58) 0.001
Pneumonia
No (n = 261) 6.1 (3.8–9.8) 1 (Ref) –
Yes (n = 15) 6.7 (0.9–37.1) 1.61 (0.43–6.01) 0.475
Tuberculosis
No (n = 261) 6.1 (3.8–9.8) 1 (Ref) –
Yes (n = 15) 6.7 (0.9–37.1) 0.96 (0.21–4.44) 0.96
Sepsis
No (n = 220) 6.8 (4.1–11.0) 1 (Ref) –
Yes (n = 67) 2.9 (0.7–11.3) 0.56 (0.22–1.39) 0.211
Diarrhea
No (n = 266) 5.6 (3.4–9.2) 1 (Ref) –
Yes (n = 10) 2.0 (4.6–56.3) 10.97 (2.94–40.98) 0.001
Diabetes
No (n = 205) 5.4 (2.9–9.5) 1 (Ref) –
Yes (n = 71) 8.5 (3.8–17.7) 1.04 (0.48–2.26) 0.928
HIV
No (n = 249) 5.6 (3.3–9.3) 1 (Ref) –
Yes (n = 27) 11.1 (3.5–30.0) 2.46 (0.96–6.30) 0.06
Table 4 Antibiotic use and
prevalence of CTX-M in gram-
negative bacteria
Patient characteristics CTX-M gram-negative bacteria
Prevalence (95% CI) Crude OR (95% CI) P value
Currently on antibiotics
No (n = 54) 3.7 (0.9–13.9) 1 (Ref) –
Yes (n = 222) 6.8 (4.1–10.9) 1.35 (0.53–3.41) 0.529
Ciprofloxacin
No (n = 258) 6.2 (3.8–9.9) 1 (Ref) –
Yes (n = 18) 5.6 (0.7–32.1) 2.62 (0.88–7.83) 0.084
Ceftriaxone
No (n = 135) 8.1 (4.5–14.2) 1 (Ref) –
Yes (n = 141) 4.3 (1.9–9.2) 0.34 (0.16–0.71) 0.004
Cotrimoxazole
No (n = 267) 6.0 (3.7–9.6) 1 (Ref) –
Yes (n = 9) 11.1 (1.3–53.4) 3.31 (0.79–13.86) 0.101
Cloxacillin
No (n = 216) 6.0 (3.5–10.1) 1 (Ref) –
Yes (n = 60) 6.6 (2.5–16.6) 0.64 (0.25–1.61) 0.342
Metronidazole
No (n = 256) 5.9 (3.2–10.7) 1 (Ref) –
Yes (n = 20) 6.5 (3.1–13.1) 1.63 (0.52–5.17) 0.405
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showed a relatively reduced risk of CTX-M gram-negative
bacteria compared to those with no prior history of admission;
AOR 0.26 (0.08–0.88), p = 0.031. An increased risk of CTX-
M gram-negative bacteria was observed for those currently on
at least one antibiotic compared to those who were not on any
antibiotics; AOR 4.02 (1.29–12.58), p = 0.017. A decreased
risk of CTX-M gram-negative bacteria was observed among
those who were currently on Ceftriaxone compared to those
who were not on Ceftriaxone; AOR 0.14(0.04–0.46), p =
0.001 and for those with wound infections was 0.24 (0.09–
0.61), p = 0.003. There is also seen a lower likelihood in pa-
tients with wound infection than those without wound
infections.
Discussion
This survey investigated the prevalence and possible risk fac-
tors for CTX-M gram-negative bacteria in hospitalized pa-
tients in Kilimanjaro, Tanzania. It is the first report to investi-
gate ESBL-producing gram-negative bacteria due to CTX-M
in clinical specimens using whole genome sequencing and not
based on phenotypic testing. To the best of our knowledge, it
is the first risk factor analysis of ESBL-producing gram-neg-
ative bacteria infections in Tanzania. The overall prevalence
of CTX-M gram-negative bacteria in this study was 13.6%.
This hospital-study’s findings are comparable with other hos-
pital studies that had previously reported low ESBL-
producing gram-negative bacteria prevalence in Gabon,
15.0% [37], and Central Africa Republic, 4 to 19% [38].
However, the report’s prevalence contrasts with 42% preva-
lence in a review on general ESBL-producing gram-negative
bacteria in East Africa hospitals [34], a 29.7% prevalence
previously reported in Kilimanjaro by Kajeguka et al. [39],
and 32.6% prevalence reported in Guinea-Bissau [22].
Further, our findings contrast with other reports on ESBL-
producing gram-negative bacteria in hospitals outside the
East African region in that they had shown higher prevalence
than in this report: Cameroon 55% [19], Ghana 49% [23],
Egypt above 45% [40], and South Africa 83% [41]. There
could be several reasons for the observed low prevalence
(13.6%) of CTX-M gram-negative bacteria, including the fact
that the majority of patients were sampled while they had been
on antibiotics for a number of days since admission. The prev-
alence of CTX-M gram-negative bacteria was observed to
decrease with hospitalization days. The use of ceftriaxone in
the majority of inpatients at KCMC is a plausible explanation
for the observed low prevalence of CTX-M, and the decrease
in prevalence over time. Moreover, the prevalence of CTX-M
at admission may be relatively high due to selection of ESBL-
producing gram-negative bacteria in the community due to
overuse of antibiotics other than ceftriaxone. A comparison
of CTX-M resistance between patients on ceftriaxone versus
patients on other cephalosporins like ceftazidime or cefepime
would have been of great interest; however, the available data
was insufficient for this analysis.
Prevalence of CTX-M gram-negative bacteria appeared to
increase with age. The numbers of patients with age more than
65 years in this study were low, so the comparison with other
publications could not be done. Other reports [42–44] have
shown adults over 65 to be almost three times at risk of infec-
tion with ESBL-producing gram-negative bacteria. Due to
their diminishing immunity and repeated hospitalization, this
group is more prone to infections including resistant bacterial
strains. However, there appears to be no statistical evidence to
support the observed proportion differences in the risks of the
CTX-M gram-negative bacteria across age groups.
We investigated whether or not sleeping on stretchers and
sleeping in corridors as proxy indicators of overcrowding
were associated with the CTX-M gram-negative bacteria. It
was found that the prevalence of CTX-M gram-negative bac-
teria in patients sleeping in ward corridors (on stretchers) as
the proper beds were all occupied and no space inside the
rooms were relatively high compared to their counterparts.
However, sleeping on stretchers and sleeping in corridors
were not significantly associated with increased risk of isolat-
ing CTX-M gram-negative bacteria.
Factors that showed statistically significant associations
with CTX-M gram-negative bacteria include prior admis-
sion, currently on antibiotics, use of Ceftriaxone, and
wound infections. This report shows that a large proportion
(71.9%) of patients was already on antibiotics therapy
when specimens were collected for microbiological analy-
ses. Prevalence of isolating CTX-M gram-negative bacte-
ria from patients who were on at least one type of antibi-
otics was higher (6.8%) than in those who were not (3.7%).
The likelihood of isolating CTX-M gram-negative bacteria
from those who were currently on antibiotics was found to
be four times higher than from those who were not on
Table 5 Multivariate logistic regression model showing adjusted ORs
for isolating CTX-M gram-negative bacteria
Patient characteristics AORa (95% CI) P value
Prior admission 0.26 (0.08–0.88) 0.031
Prior medication 1.50 (0.62–3.62) 0.368
Currently admitted in surgical ward 0.70 (0.28–1.76) 0.444
Patient inside the room 0.76 (0.32–1.78) 0.522
Over 4 days of hospitalization 0.72 (0.31–1.71) 0.462
Currently on antibiotic 4.02 (1.29–12.58) 0.017
Currently on Ciprofloxacin 0.84 (0.21–3.35) 0.804
Currently on Ceftriaxone 0.14 (0.04–0.46) 0.001
HIV positive 1.15 (0.37–3.55) 0.804
Wound infection 0.24 (0.09–0.61) 0.003
aAdjusted odds ratio
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antibiotics therapy. Reports have shown that the risk of
developing antibiotics resistance in societies where antibi-
otics are excessively used is high [44, 45] due to antimi-
crobial resistance selection pressure. In KCMC, being a
referral hospital, the patients coming to seek medical ser-
vices are those who might have used antibiotics but treat-
ment failed due to carriage of resistant strains prior to their
referrals. Furthermore, given the fact that patients are re-
ferred to our hospital from different healthcare facilities,
the likelihood of patients to have been on antibiotics is
high. Self-referred patients rarely have a paper record of
prior medications. Empirical therapy, self-medication, and
over-the-counter medications are common in low-income
countries (LIC) [46–48]. This experience-based therapy
practiced by physicians in LIC is one of the factors fuelling
emergence of resistance, particularly when unnecessarily
switching to higher generations of antibiotics.
Ceftriaxone has been a drug of choice by many physi-
cians in our setting due to its broad-spectrum activity. Over
51% of the analyzed gram-negative bacteria were isolated
from patients who were on Ceftriaxone. The prevalence of
CTX-M gram-negative bacteria was 4.3% from patients
who were on Ceftriaxone, compared to 8.1% for those
who were not. The likelihood of isolating CTX-M gram-
negative bacteria from those who were currently on
Ceftriaxone appeared to be seven times lower than those
who were not treated with Ceftriaxone. As self-medication
with Ceftriaxone is uncommon due to its high cost, this
suggests that treatment with injectable Ceftriaxone in the
hospital was effective against CTX-M gram-negative
bacteria. Nevertheless, its prescription should be guided
by microbiological results.
A substantial proportion (34.5%) of CTX-M gram-neg-
ative bacteria was isolated from patients who had a history
of admission (hospitalization). The prevalence of isolating
CTX-M gram-negative bacteria from patients with no his-
tory of admission (hospitalization) was 6.4%, higher than
5.1% in those with hospitalization history. However, the
likelihood of isolating CTX-M gram-negative bacteria
from patients with history of admission was approximately
four times lower than their counterparts, consistent with a
recent report [49] that showed a 32% lower risk of ESBL-
producing gram-negative bacteria among previously hos-
pitalized patients. It could be that during past admissions,
these patients were put on Ceftriaxone doses that had suc-
cessfully treated CTX-M gram-negative bacteria. This re-
port suggests that Ceftriaxone could be effective against
CTX-M gram-negative bacteria. Furthermore, the observed
high risk of CTX-M gram-negative bacteria among those
who had no prior admission could be explained by the fact
that they were carrying resistant CTX-M gram-negative
bacteria from the community. However, these findings
are different from reports [20, 45, 50, 51] which found that
previous admission and use of cephalosporins increase the
risk of CTX-M gram-negative bacteria.
A benefit of this study is its contribution to a larger
project in which we have been able to build an infrastruc-
ture and implement next-generation sequencing (NGS)
techniques for clinical diagnostics. For the current report,
we have been able to analyze clinical specimens by doing
whole genome sequencing to identify CTX-M genes that
code for ESBL. We acknowledge that several limitations
need to be addressed. Firstly, wound and pus swab spec-
imens make up the majority of samples studied.
Microbiology results do not always represent the cause
of the infection. Secondly, in this report, ESBL-
producing gram-negative bacteria resistance was defined
based on the presence of the CTX-M gene. Despite its
important role in resistance, this restricted definition
means we may have underestimated the ESBL-producing
gram-negative bacteria prevalence. Underestimation of
ESBL-producing gram-negative bacteria resistance could
also be attributed to sampling patients who were already
on antibiotics treatment. Thirdly, though our report high-
lights some key aspects regarding prevalence and risk
factors for ESBL-producing gram-negative bacteria resis-
tance due to CTX-M gram-negative bacteria that are im-
portant in programming for antimicrobial control, the
study was insufficiently powered to confidently draw con-
clusions about all suspected variables, especially those
that appeared contradicting. Fourth, this study was unable
to differentiate between community-acquired and
hospital-acquired ESBL-producing gram-negative bacteria
as clinical sampling was done during, rather than prior to
hospitalization. Finally, the widespread use of antibiotics
in our settings makes it difficult to ascertain whether or
not exposure to antibiotics preceded the emergency of
ESBL-producing gram-negative bacteria resistance due
to CTX-M.
Conclusions
In conclusion, although the prevalence of ESBL-producing
gram-negative bacteria due to CTX-M in this setting was
found to be low, it is worthwhile to devise approaches aimed
at containing the situation before it gets out of control. To
properly stop their spread in the hospital, apart from direct
containment methods, we recommend setting up a hospital
surveillance system that takes full advantage of the available
NGS facility to routinely screen for other resistant bacterial
genes.
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